Lasix: profile and news

New Erbitux approval to head off cancer  06 Mar 2006
Erbitux (cetuximab) is an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor (EGFR), which is responsible for tumour growth and spread ... - In-PharmaTechnologist.com,

FDA Approves ERBITUX(R) (Cetuximab) for Treatment of Head and Neck ...  Mar 1, 2006
IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the US Food and Drug Administration (FDA) has approved ERBITUX(R) (Cetuximab), an IgG1 ... - Genetic Engineering News,

MultiVu Video Feed: FDA Approves ERBITUX(R) (Cetuximab) for ...  Mar 1, 2006
Today, the US Food and Drug Administration (FDA) approved ERBITUX(R) (Cetuximab) in combination with radiation therapy for the treatment of a certain type of ... - Finanzen.net,

Cetuximab Improves Outcomes of Head and Neck Cancers  Feb 10, 2006
FEB 09, 2006 (Reuters Health) - Treating patients with locoregionally advanced squamous-cell carcinoma of the head and neck with cetuximab plus radiotherapy ... - Cancerpage.com,

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the ...  Feb 9, 2006
Background We conducted a multinational, randomized study to compare radiotherapy alone with radiotherapy plus cetuximab, a monoclonal antibody against the ... - New England Journal of Medicine (subscription),

FDA Approves Erbitux (Cetuximab), First Head & Neck Cancer ...  Mar 2, 2006
BETHESDA, MD -- March 2, 2006 -- The Food and Drug Administration (FDA) today announced the approval of Erbitux (cetuximab) for use in combination with ... - DG News

Im Clone Scandal Free And Developing New Treatments  Mar 2, 2006
The US Food and Drug Administration (FDA) has approved ERBITUX(R) (Cetuximab), for the treatment of squamous cell carcinoma of the head and neck and is the ... - All Headline News

International award honors MD Anderson President for pioneering ...  Feb 27, 2006
The antibody, called Cetuximab (Erbitux(r)) acts by binding to the receptor, and was the first example of an anticancer agent which inhibits critical ... - EurekAlert (press release),

Erbitux Approved to Treat Head and Neck Cancers  Mar 3, 2006
FRIDAY, March 3 (HealthDay News) -- The drug Erbitux (cetuximab) has been approved to treat cancers of the head and neck, the US Food and Drug Administration ... - Forbes

FDA OKs Erbitux for other cancers  Mar 3, 2006
Erbitux, formally known as cetuximab, was the drug at the center of the ImClone Systems stock scandal that sent Martha Stewart and ImClone founder Sam Waksal ... - Albuquerque Tribune,

FDA approves new drug for head & neck cancer  Mar 3, 2006
The drug, cetuximab, marketed as ERBITUX® by ImClone Systems and Bristol-Myers Squibb is a new generation drug that specifically targets a protein regulating ... - Cancerfacts.com,

Erbitux Now Approved for Head and Neck Cancers  Mar 3, 2006
The US Food and Drug Administration has approved the drug Erbitux (cetuximab) for certain patients with cancers of the head and neck. ... - ACS News Center,

CytoDyn Welcomes Dr. Trevor Hawkins to Its Scientific Advisory ...  Mar 3, 2006
...and Bristol-Myers Squibb Company (NYSE: BMY) announced recently that the US Food and Drug Administration (FDA) has approved ERBITUX® (Cetuximab), an IgG1 ... - Financial News USA (press release),

FDA Approves Erbitux® For Treatment of Head and Neck Cancer  Mar 2, 2006
The United States Food and Drug Administration (FDA) has approved the monoclonal antibody Erbitux® (cetuximab) for the treatment of head and neck cancer. ... - Cancer Consultants (press release),

Drug Extends Head and Neck Cancer Survival  Feb 8, 2006
8 (HealthDay News) -- Adding the drug cetuximab to radiation therapy for head and neck cancer can boost patient survival rates by about 20 months without ... - Forbes

Merck KGaA Receives EMEA Positive Opinion for Erbituxin Head and ...  Feb 23, 2006
...for Human Use (CHMP), the scientific committee of the EMEA (European Medicines Agency), for its application to extend the use of Erbitux® (cetuximab) to the ... - PharmaLive.com (press release),

MPs mourn death of cancer victim  Feb 10, 2006
...who is campaigning for an end to postcode prescribing, highlighted Jack's death and said he may have survived longer if he had received the drug, Cetuximab. ... - Sunderland Echo,

Head, neck cancer drug in Martha Stewart trial gets federal OK  Mar 1, 2006
Erbitux, formally known as cetuximab, was at the center of the ImClone Systems stock scandal that sent Stewart and company founder Sam Waksal to prison. ... - Newsday,

FDA approves new cancer drug Erbitux  Mar 2, 2006
The FDA approved Erbitux (cetuximab) for use in combination with radiation therapy to treat patients with squamous cell cancer of the head and neck that can ... - Monsters and Critics.com,

FDA Approves Erbitux To Treat Head And Neck Cancer  Mar 2, 2006
...(AHN) - The US Food and Drug Administration approves Erbitux (cetuximab) for use in combination with radiation therapy to treat patients with squamous cell ... - All Headline News

FDA Approves Erbitux for Squamous Cell Head-and-Neck Cancer  Mar 2, 2006
ROCKVILLE, March 2 - The FDA has approved Erbitux (cetuximab) for treatment of advanced squamous cell cancer of the head and neck. ... - MedPage Today,

Erbitux Approved for Head and Neck Cancers  Mar 2, 2006
By Rachael Myers Lowe, cancerpage.com. ( March 1, 2006 ) – The FDA has approved the drug Erbitux (cetuximab) for use in head and neck cancer. ... - Cancerpage.com,

(PRN) - Following Is a Test Release ... [+]  Mar 1, 2006
Dividend ... [+. PRN) - MultiVu Video Feed: FDA Approves ERBITUX(R) (Cetuximab) for Treatment of Head and Neck Cancer ... [+. PRN ... - Bolsamania.com,

New Drug For Head & Neck Cancer  Mar 2, 2006
...chemotherapy. Erbitux is made by ImClone Systems and distributed by Bristol-Myers Squibb. The drug is formally known as Cetuximab. It ... - KOLD-TV,

ImClone’s Erbitux Receives FDA Label In Head And Neck Cancer  Mar 2, 2006
Specifically, the monoclonal antibody Erbitux (cetuximab), which inhibits epidermal growth factor, was cleared by the FDA for treatment of locally or ... - BioWorld Online (subscription),

Addition of Erbitux® to Radiation Therapy Improves Survival in ...  Feb 9, 2006
According to a recent article published in the New England Journal of Medicine, the addition of Erbitux® (cetuximab) to radiation therapy improves survival ... - Cancer Consultants (press release),

Erbitux gets US green light for head and neck cancer  Mar 2, 2006
Erbitux (cetuximab) has been cleared by the US Food and Drug Administration (FDA) for use in combination with radiation therapy in the treatment of locally or ... - Pharma Times (subscription),

FDA Approves First Head & Neck Cancer Treatment in 45 Years  Mar 2, 2006
Washington, DC - infoZine - The Food and Drug Administration (FDA) yesterday announced the approval of Erbitux (cetuximab) for use in combination with ... - Kansas City infoZine,

FDA Approves First Head & Neck Cancer Treatment in 45 Years Data ...  Mar 1, 2006
The Food and Drug Administration (FDA) today announced the approval of Erbitux (cetuximab) for use in combination with radiation therapy to treat patients with ... - FDA.gov

Erbitux® Plus Chemotherapy and Radiation Therapy Promising in ...  Mar 2, 2006
According to results recently published in the Journal of Clinical Oncology, the combination of Erbitux® (cetuximab) plus chemotherapy and radiation therapy ... - Cancer Consultants (press release),

Better right track than fast track  Feb 19, 2006
...row over Herceptin for use in early breast cancer and the problems patients have had accessing the colorectal cancer drug Cetuximab, have graphically ... - ic Wales,

DRUG-BAN GRANDAD DIES  Feb 7, 2006
The Echo told last month how Mr Wilson, of Donwell, Washington, was refused the drug, Cetuximab, which he believed may have prolonged his life. ... - Sunderland Echo,

Erbitux-Based Chemoradiation May Help in Head-and-Neck Cancer  Feb 8, 2006
8 - Erbitux (cetuximab) combined with radiotherapy may be a viable alternative for patients with head-and-neck cancer who can't tolerate platinum-based ... - MedPage Today,

Addition of Erbitux® to Radiation Therapy Improves Survival in ...  Feb 22, 2006
A multi-center randomized trial has shown that the addition of Erbitux® (cetuximab) to radiation therapy improves survival over radiation therapy alone in the ... - Cancer Consultants (press release),

ImClone Systems Issues Statement Regarding Positive Opinion from ...  Feb 23, 2006
Human Use (CHMP), the scientific committee of the EMEA (European Medicines Agency), for its application to extend the use of ERBITUX(R) (Cetuximab), an IgG1 ... - Business Wire (press release),

European Medicines Agency: Committee for Medicinal Products for ...  Feb 23, 2006
Erbitux (cetuximab) from Merck KGaA, to extend its indication to add the treatment of locally advanced squamous cell cancer of the head and neck in combination ... - PharmaLive.com (press release),

Give Us All Wonder Drugs Now ; RIVALS GANG UP ON HEALTH MINISTER ...  Feb 7, 2006
To cut corners would be highly irresponsible.". CETUXIMAB a last-stage treatment for patients with advanced colorectal cancer. Although ... - International News Service,

ImClone Systems Announces Complete Enrollment of Several Studies ...  Feb 16, 2006
...patient enrollment has been completed in three international, registrational Phase III clinical trials examining the use of ERBITUX(R) (cetuximab) in three ... - Genetic Engineering News,

Combo Treatment Benefits Head and Neck Cancer  Feb 9, 2006
They say the addition of the drug cetuximab resulted in longer disease-free times and lower death rates when compared to results for 213 similar patients ... - Ivanhoe,

ImClone Systems Announces Complete Enrollment of Several Studies ...  Feb 16, 2006
...full patient enrollment has been completed in threeinternational, registrational Phase III clinical trials examining theuse of ERBITUX(R) (cetuximab) in three ... - Finanzen.net,

AUDIO SUMMARY  Feb 9, 2006
Featured are articles on saw palmetto for benign prostatic hyperplasia, radiotherapy plus cetuximab for head and neck cancer, SSRIs in pregnancy and persistent ... - New England Journal of Medicine (subscription),

Meditech to Showcase Cancer Research at International Forum  Feb 2, 2006
...preeminent. cetuximab (Erbitux®). ... that. we’ve generated using the HyACT™ platform with drugs such as cetuximab and gemcitabine.�. - PharmaLive.com (press release),

ImClone Systems Announces Complete Enrollment of Several Studies ...  Feb 17, 2006
...full patient enrollment has been completed in three international, registrational Phase III clinical trials examining the use of ERBITUX® (cetuximab) in three ... - Financial News USA (press release),

MP condemns postcode lottery on drugs  Feb 2, 2006
...on "humanitarian grounds". Mr Wilson, 66, is suffering from bowel cancer but has been refused Cetuximab by the NHS. Mr Fergus, who ... - ic Teesside.co.uk,

Pharmaceutical Companies Look to Biomarkers to Help in Increasing ...  Feb 2, 2006
...for molecularly targeted oncology drugs, including trastuzumab (Genentech's Herceptin), imatinib mesylate (Novartis's Gleevec), and cetuximab (ImClone's Erbitux ... - PharmaLive.com (press release),

Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function. Except in life-threatening situations, avoid this combination.

Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity. Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.

Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.

Lithium generally should not be given with diuretics because they reduce lithium's renal clearance and add a high risk of lithium toxicity.

Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs. Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.

Furosemide may decrease arterial responsiveness to norepinephrine. However, norepinephrine may still be used effectively.

Tablets

Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide. Patients receiving both drugs should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved. The intake of furosemide and sucralfate should be separated by at least two hours.

Tablets, Injection, and Oral Solution

One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency. There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs.

Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis. Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation. Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.